KRAS G12C Crystal Structure with Phthalazine Inhibitor from Clinical Trial

C. Mohr provides a crystal structure dataset of the human KRAS G12C protein covalently bound to a phthalazine inhibitor. The description notes the inhibitor is currently in a phase I clinical trial (NCT03600883). The dataset is available via the paperswithcode platform under an Open Access (green) license.

Use Cases

• Analyzing protein-ligand binding interactions based on the described crystal structure.
• Supporting structure-based drug design for KRAS G12C inhibitors mentioned in the description.
• Validating computational docking models using the experimentally determined structure of the phthalazine inhibitor complex.

Strengths

• Dataset is linked to an active phase I clinical trial (NCT03600883), providing a direct research context.
• The structure involves a specific, clinically relevant protein target (human KRAS G12C).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

C. Mohr via paperswithcode